<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:regsci-ojs-tamu.tdl.org:article/135</identifier>
				<datestamp>2023-04-11T02:38:41Z</datestamp>
				<setSpec>regsci:RA</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research</dc:title>
	<dc:creator xml:lang="en">Shibata, Shoyo</dc:creator>
	<dc:creator xml:lang="en">Ozaki, Koken</dc:creator>
	<dc:creator xml:lang="en">Suzuki, Takeshi</dc:creator>
	<dc:subject xml:lang="en">Japan</dc:subject>
	<dc:subject xml:lang="en">pharmaceutical industry</dc:subject>
	<dc:subject xml:lang="en">drug pricing</dc:subject>
	<dc:subject xml:lang="en">regulatory science</dc:subject>
	<dc:subject xml:lang="en">clinical development</dc:subject>
	<dc:subject xml:lang="en">marketing strategy</dc:subject>
	<dc:subject xml:lang="en">Japan</dc:subject>
	<dc:subject xml:lang="en">pharmaceutical industry</dc:subject>
	<dc:subject xml:lang="en">drug pricing</dc:subject>
	<dc:subject xml:lang="en">regulatory science</dc:subject>
	<dc:subject xml:lang="en">clinical development</dc:subject>
	<dc:subject xml:lang="en">marketing strategy</dc:subject>
	<dc:description xml:lang="en">The Japanese pharmaceutical market is one of the largest in the world. The Japanese government has increasingly been trying to control rising health care costs, and as a result, pharmaceutical companies are expecting that fewer opportunities will be available to command a higher price based on higher levels of innovation; this will likely lead to decreased interest in research and development (R&amp;amp;D) activities. With this background, the purpose of this article is to review current perspectives for R&amp;amp;D by the Japanese pharmaceutical industry, and to discuss the limitations and challenges for further research from the regulatory science and management perspectives. Given the substantial amount of evidence of regulatory science and management perspectives from the pharmaceutical industry outside of Japan and the limited amount of evidence from inside of Japan, it is important to review perspectives focusing on the Japanese pharmaceutical industry in comparison with those from other countries to understand the complexities of the Japanese pharmaceutical market, as well as the limitations and challenges associated with increasing productivity.
https://doi.org/10.21423/jrs-v08shoyo</dc:description>
	<dc:publisher xml:lang="en">Office of the Texas State Chemist</dc:publisher>
	<dc:date>2020-11-08</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://regsci-ojs-tamu.tdl.org/regsci/article/view/135</dc:identifier>
	<dc:identifier>10.21423/JRS-V08SHOYO</dc:identifier>
	<dc:source xml:lang="en">Journal of Regulatory Science; Vol. 8 (2020); 1-13</dc:source>
	<dc:source>2377-3537</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://regsci-ojs-tamu.tdl.org/regsci/article/view/135/198</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2020 Shoyo Shibata, Koken Ozaki, Takeshi Suzuki</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
